Gordon K - Search Results

1

Systematic review of the real-world evidence of adalimumab safety in psoriasis registries.

Strober B, Crowley J, Langley RG, Gordon K, Menter A, Leonardi C, Arikan D, Valdecantos WC. Strober B, et al. Among authors: gordon k. J Eur Acad Dermatol Venereol. 2018 Dec;32(12):2126-2133. doi: 10.1111/jdv.15203. Epub 2018 Aug 28. J Eur Acad Dermatol Venereol. 2018. PMID: 30067882

2

Biologic therapy for psoriasis: the new therapeutic frontier.

Singri P, West DP, Gordon KB. Singri P, et al. Arch Dermatol. 2002 May;138(5):657-63. doi: 10.1001/archderm.138.5.657. Arch Dermatol. 2002. PMID: 12020229

3

Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts.

Gordon KB, Vaishnaw AK, O'Gorman J, Haney J, Menter A; Alefacept Clinical Study Group. Gordon KB, et al. Arch Dermatol. 2003 Dec;139(12):1563-70. doi: 10.1001/archderm.139.12.1563. Arch Dermatol. 2003. PMID: 14676071 Clinical Trial.

4

Efalizumab for patients with moderate to severe plaque psoriasis: a randomized controlled trial.

Gordon KB, Papp KA, Hamilton TK, Walicke PA, Dummer W, Li N, Bresnahan BW, Menter A; Efalizumab Study Group. Gordon KB, et al. JAMA. 2003 Dec 17;290(23):3073-80. doi: 10.1001/jama.290.23.3073. JAMA. 2003. PMID: 14679270 Clinical Trial.

5

Remittive effects of intramuscular alefacept in psoriasis.

Gordon KB, Langley RG. Gordon KB, et al. J Drugs Dermatol. 2003 Dec;2(6):624-8. J Drugs Dermatol. 2003. PMID: 14711140 Clinical Trial.

6

Extended efalizumab therapy sustains efficacy without increasing toxicity in patients with moderate to severe chronic plaque psoriasis.

Gottlieb AB, Gordon KB, Lebwohl MG, Caro I, Walicke PA, Li N, Leonardi CL; EFALIZUMAB STUDY GROUP. Gottlieb AB, et al. J Drugs Dermatol. 2004 Nov-Dec;3(6):614-24. J Drugs Dermatol. 2004. PMID: 15624744 Clinical Trial.

7

Definitions of measures of effect duration for psoriasis treatments.

Gordon KB, Feldman SR, Koo JY, Menter A, Rolstad T, Krueger G. Gordon KB, et al. Arch Dermatol. 2005 Jan;141(1):82-4. doi: 10.1001/archderm.141.1.82. Arch Dermatol. 2005. PMID: 15655149 No abstract available.

8

Psoriasis treatment: current and emerging directed therapies.

Winterfield LS, Menter A, Gordon K, Gottlieb A. Winterfield LS, et al. Among authors: gordon k. Ann Rheum Dis. 2005 Mar;64 Suppl 2(Suppl 2):ii87-90; discussion ii91-2. doi: 10.1136/ard.2004.032276. Ann Rheum Dis. 2005. PMID: 15708946 Free PMC article. Review.

9

Extended efalizumab therapy improves chronic plaque psoriasis: results from a randomized phase III trial.

Leonardi CL, Papp KA, Gordon KB, Menter A, Feldman SR, Caro I, Walicke PA, Compton PG, Gottlieb AB; Efalizumab Study Group. Leonardi CL, et al. J Am Acad Dermatol. 2005 Mar;52(3 Pt 1):425-33. doi: 10.1016/j.jaad.2004.09.029. J Am Acad Dermatol. 2005. PMID: 15761420 Clinical Trial.

10

Infliximab treatment results in significant improvement in the quality of life of patients with severe psoriasis: a double-blind placebo-controlled trial.

Feldman SR, Gordon KB, Bala M, Evans R, Li S, Dooley LT, Guzzo C, Patel K, Menter A, Gottlieb AB. Feldman SR, et al. Among authors: gordon kb. Br J Dermatol. 2005 May;152(5):954-60. doi: 10.1111/j.1365-2133.2005.06510.x. Br J Dermatol. 2005. PMID: 15888152 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,941 results

Search Page

Filters